Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.8503
+0.06748.61%
Volume:13.44M
Turnover:11.20M
Market Cap:185.37M
PE:-3.29
High:0.8799
Open:0.8326
Low:0.7865
Close:0.7829
52wk High:3.10
52wk Low:0.7010
Shares:218.00M
Float Shares:185.00M
Volume Ratio:0.71
T/O Rate:7.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2583
EPS(LYR):-1.2551
ROE:-249.75%
ROA:-63.44%
PB:-39.02
PE(LYR):-0.68

Loading ...

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 19

Humacyte Presents 36-Month Symvess Durability and Safety Data From V005 Trial at VESS 2026

Reuters
·
Feb 18

Why Humacyte (HUMA) Is Up 5.1% After New DoD Funding Backs Symvess Trauma Use

Simply Wall St.
·
Feb 12

Humacyte (HUMA) Valuation Check As DoD Funding Highlights Battlefield Vascular Repair Potential

Simply Wall St.
·
Feb 10

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 10

Humacyte Shares Climb After Pentagon Issues Funding for Vascular Repair Tech

Dow Jones
·
Feb 10

Press Release: Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Dow Jones
·
Feb 09

Humacyte Inc - Symness Is Only FDA-Approved Bioengineered Blood Vessel

THOMSON REUTERS
·
Feb 09

Humacyte Is Maintained at Buy by Benchmark

Dow Jones
·
Jan 21

Humacyte price target lowered to $10 from $11 at Benchmark

TIPRANKS
·
Jan 21

Benchmark Co. Sticks to Its Buy Rating for Humacyte (HUMA)

TIPRANKS
·
Jan 21

While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most

Simply Wall St.
·
Jan 13

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 08

Humacyte Reports Symvess Reduces Costly Complications in Extremity Arterial Injury Repair

Reuters
·
Jan 08

BRIEF-Humacyte Inc Announces Planned Marketing Authorization Application For Symvess In Israel

Reuters
·
Jan 05

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 05

Humacyte Inc: Announces Planned Marketing Authorization Application for Symvess in Israel

THOMSON REUTERS
·
Jan 05

Humacyte to Seek Israeli Approval for Symvess in Vascular Trauma Repair

Reuters
·
Jan 05

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 22, 2025

Humacyte Reports Long-Term Success of Symvess in Extremity Trauma Repair

Reuters
·
Dec 22, 2025